Scientific Interchange & Workshop

On May 31, 2025, a select group of US medical and thoracic oncologists from academic and cancer specialty institutions participated in a workshop held in conjunction with the 2025 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The participants discussed current and emerging therapeutic strategies in treating patients with EGFR-mutant (EGFRm),advanced non–small cell lung cancer (NSCLC). The session was moderated by Helena Yu, MD, who led discussions on managing the balance between improved efficacy outcomes and increased toxicity with combination therapies, and sequencing strategies for first-line and subsequent treatments.

On June 13, 2025, a select group of experts in multiple myeloma (MM) participated in an OncLive® scientific interchange and workshop to discuss treatment strategies in relapsed/refractory MM (R/R MM). Moderated by Peter Voorhees, MD, the discussion covered insights on the evolving role of CAR T, emerging therapies that may impact the current treatment landscape, and various treatment strategies with bispecific antibodies in R/R MM.

On June 1, 2025, OncLive® convened a group of early career medical oncologists specializing in thoracic malignancies to discuss pivotal abstracts from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO 2025). The session was moderated by Eric K. Singhi, MD, with faculty providing real-world perspectives on emerging therapies, treatment sequencing challenges, and evolving biomarker strategies. The discussion centered on antibody-drug conjugates (ADCs), targeted therapies for oncogene-driven NSCLC, perioperative treatment approaches, and novel diagnostic tools.

On June 2, 2025, a group of oncologists gathered for an in-person workshop at the 2025 Annual Meeting of the American Society of Clinical Oncology to discuss advances in cutaneous squamous cell carcinoma (cSCC) treatment. Moderated by Soo Park, MD, the session focused on adjuvant, high-risk neoadjuvant and metastatic treatment, including the use of immune checkpoint inhibitors (ICIs). Faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.

On May 6, 2025, a select group of US medical oncologists and 1 radiation oncologist from academic and cancer specialty institutions participated in a virtual workshop to discuss insights and considerations for identifying and managing HER2-mutant non–small cell lung cancer (NSCLC). The session was moderated by Joshua K. Sabari, MD, who obtained perspectives on testing for and management of HER2 NSCLC and recent trials of antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) for the treatment of HER2-mutant NSCLC.

On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape. Caroline Robert, MD, PhD, led the discussion, obtaining perspectives on the available evidence about immunotherapy options and insights into treatment preferences for high-risk cutaneous squamous cell carcinoma that is either locally advanced (laCSCC) or metastatic (mCSCC) and advanced/metastatic cutaneous melanoma.

On March 8, 2025, a select group of experts in breast cancer (BC) participated in a live workshop to discuss the place of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic BC (MBC). Moderated by Hope S. Rugo, MD, the discussion included the role of oral SERDs as monotherapy or in combination, the optimal integration of SERDs into standard-of-care therapies, and practical approaches including biomarker testing and toxicity management.

Disease Mechanisms, Diagnostic Challenges, and Multidisciplinary Treatment Strategies